Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gregory J. Withbroe is active.

Publication


Featured researches published by Gregory J. Withbroe.


Bioorganic & Medicinal Chemistry | 2003

Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity: 1-{4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(R) ethanol

Banavara L. Mylari; Gregory J. Withbroe; David A. Beebe; Nathaniel S. Brackett; Edward L. Conn; James B. Coutcher; Peter J. Oates; William James Zembrowski

Two new templates, (R) 2-hydroxyethyl-pyridine and (R) 2-hydroxyethyl-triazine, were used to design novel sorbitol dehydrogenase inhibitors (SDIs). The design concept included spawning of these templates to function as effective ligands to the catalytic zinc within the enzyme through incorporation of optimally substituted piperazino-triazine side chains so as to accommodate the active site in the enzyme for efficient binding. This strategy resulted in orally active SDIs, which penetrate key tissues, for example, sciatic nerve of chronically diabetic rats. The latter template led to the design of the title inhibitor, 33, which normalized the elevated sciatic nerve fructose by 96% at an oral dose of 10mg/kg.


Synthetic Communications | 2008

Synthesis of (1‐(Aminomethyl)‐2,3‐dihydro‐1H‐inden‐3‐yl)methanol: Structural Confirmation of the Main Band Impurity Found in Varenicline® Starting Material

Frank Robert Busch; Paul E. Concannon; Robert Eugene Handfield; Jason D. McKinley; Megan E. McMahon; Robert A. Singer; Timothy J. N. Watson; Gregory J. Withbroe; Mariano Stivanello; Lucia Leoni; Chiara Bezze

Abstract Described here is the synthesis of (1‐(aminomethyl)‐2,3‐dihydro‐1H‐inden‐3‐yl)methanol 1, the previously unidentified impurity found in the synthesis of 2,1 providing a confirmation of the structure. Fabbrica Italiano Sintetici (FIS), working in conjunction with Pfizer Groton, reported an unidentified impurity, referred to as the “main band impurity”, in 2 at levels of 0.4 to 0.8%. The structure was postulated to be 1, the open‐ring product of the lithium aluminum hydride (LAH) reduction of 3 to 2. Although the cis isomer of 1 was previously reported in the literature,2 a much shorter racemic synthesis was developed using intermediates employed for the production of Varenicline®. Several reducing agents were screened for the synthesis of 1, with LiAlH4 followed by basic workup conditions giving optimal results. High performance liquid chromatography (HPLC) analysis ultimately confirmed the structure of 1 as the main band impurity generated during the synthesis of 2.


Organic Process Research & Development | 2008

Streamlined Synthesis of the Bippyphos Family of Ligands and Cross-Coupling Applications

Gregory J. Withbroe; Robert A. Singer; Janice E. Sieser


Journal of Medicinal Chemistry | 2005

A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners

Banavara L. Mylari; Sandra J. Armento; David A. Beebe; Edward L. Conn; James B. Coutcher; Michael S. Dina; Melissa T. O'gorman; Michael C. Linhares; William H. Martin; Peter J. Oates; David A. Tess; Gregory J. Withbroe; William James Zembrowski


Journal of Medicinal Chemistry | 2003

A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one

Banavara L. Mylari; Sandra J. Armento; David A. Beebe; Edward L. Conn; James B. Coutcher; Michael S. Dina; Melissa T. O'gorman; Michael C. Linhares; William H. Martin; Peter J. Oates; David A. Tess; Gregory J. Withbroe; William James Zembrowski


Journal of Medicinal Chemistry | 2002

A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action: 1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol

Banavara L. Mylari; Peter J. Oates; William James Zembrowski; David A. Beebe; Edward L. Conn; James B. Coutcher; Melissa T. O'gorman; Michael C. Linhares; Gregory J. Withbroe


Organic Process Research & Development | 2014

Development of an Efficient Pd-Catalyzed Coupling Process for Axitinib

Brian P. Chekal; Steven M. Guinness; Brett M. Lillie; Robert William Mclaughlin; Charles W. Palmer; Ronald J. Post; Janice E. Sieser; Robert A. Singer; Gregory W. Sluggett; Rajappa Vaidyanathan; Gregory J. Withbroe


Organic Process Research & Development | 2013

A Robust, Streamlined Approach to Bosutinib Monohydrate

Gregory J. Withbroe; Chris Seadeek; Kevin P. Girard; Steven M. Guinness; Brian C. Vanderplas; Rajappa Vaidyanathan


Archive | 2006

Preparation of high purity substituted quinoxaline

Frank Robert Busch; Joel M. Hawkins; Lasson Georgios Mustakis; Terry Gene Sinay; Timothy J. N. Watson; Gregory J. Withbroe


Archive | 2007

Varenicline standards and impurity controls

Karen S. Bronk; Frank Robert Busch; Terry Gene Sinay; Gregory J. Withbroe

Researchain Logo
Decentralizing Knowledge